ArticleBMC infectious diseases2026
Integrated analysis of miRNA and transcription factor gene expression profiles associated with anti-tuberculosis treatment responses.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTuberculosis (TB) is a severe respiratory illness that can lead to opportunistic infections in individuals with weakened immune systems. Accurate diagnosis and monitoring of treatment responses are essential. In this study, we analyzed the miRNA and mRNA profiles of 12 patients with active TB (ATB) before and after treatment.
methodsWe identified differentially expressed (DE) microRNAs (miRNAs) and messenger RNAs (mRNAs), and investigated the relationship between the expression of miRNAs and their target mRNAs. We validated the selected miRNA levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
resultsAfter six months of treatment, miRNA profiling of patients with ATB revealed nine miRNAs with altered expression levels. Anti-TB treatment restored miR-223-3p, miR-6787-3p, miR-338-5p, miR-1273h-3p, miR-1288-3p, miR-200c-3p, miR-3074-3p, miR-433-3p, and miR-200b-3p levels to those observed in healthy controls. We conducted qRT-PCR to verify the top nine DE miRNAs using an additional set of 22 blood samples. The results showed that all nine DE miRNAs exhibited decreased expression after the completion of therapy. mRNA sequencing was performed on the same blood samples. This analysis confirmed the significant DE of 75 mRNAs, of which 13 (AFF3, NT5C1B, HIC2, SPATA25, ZFYVE9, HTR7, LRRC8E, METTL2A, PLD4, RGS5, EME2, TIGD5, and PEG10) interacted with the miRNAs pre-analyzed using the miRWalk miRNA target prediction and analysis program.
conclusionThe DE miRNAs identified in this study may serve as potential biomarkers for monitoring the therapeutic efficacy of ATB. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.